Literature DB >> 23500206

Opioids, sensory systems and chronic pain.

Christoph Stein1.   

Abstract

Opioids are the oldest and most potent drugs for the treatment of severe pain. Their clinical application is undisputed in acute pain (e.g. associated with trauma or surgery) but their long-term use in chronic pain has met increasing scrutiny. Therefore, this article will review sensory mechanisms related to opioid analgesia and side effects with a special emphasis on chronic pain. Central and peripheral sites of analgesic actions and side effects, as well as conventional and novel opioid compounds will be discussed. Since pain is a complex bio-psycho-social phenomenon, non-pharmacological considerations important for the understanding of opioid analgesic efficacy are also included. Finally, examples of challenging clinical situations such as the perioperative management of patients receiving long-term opioid treatment are illustrated.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction; Arthritis; Cancer pain; Chonic pain; Clinical applications; Dependence; Dorsal root ganglion; Inflammation; Morphine; Non-malignant pain; Peripheral; Postoperative pain; Surgery; Tolerance

Mesh:

Substances:

Year:  2013        PMID: 23500206     DOI: 10.1016/j.ejphar.2013.01.076

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  35 in total

1.  The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.

Authors:  Biao Xu; Mengna Zhang; Xuerui Shi; Run Zhang; Dan Chen; Yong Chen; Zilong Wang; Yu Qiu; Ting Zhang; Kangtai Xu; Xiaoyu Zhang; Wolfgang Liedtke; Rui Wang; Quan Fang
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

2.  T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice.

Authors:  Lilian Basso; Laure Garnier; Arnaud Bessac; Jérôme Boué; Catherine Blanpied; Nicolas Cenac; Sophie Laffont; Gilles Dietrich
Journal:  J Gastroenterol       Date:  2017-04-19       Impact factor: 7.527

Review 3.  Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials.

Authors:  Joseph B O'Brien; Joshua C Wilkinson; David L Roman
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.157

4.  BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice.

Authors:  Ning Li; Zheng-Lan Han; Zi-Long Wang; Yan-Hong Xing; Yu-Long Sun; Xu-Hui Li; Jing-Jing Song; Ting Zhang; Run Zhang; Meng-Na Zhang; Biao Xu; Quan Fang; Rui Wang
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

5.  Effects of intramuscular morphine in men and women with temporomandibular disorder with myofascial pain.

Authors:  Soo-Kyung Kang; Yeon-Hee Lee; Hyeji Park; Jin Y Ro; Q-Schick Auh
Journal:  Oral Dis       Date:  2018-07-06       Impact factor: 3.511

6.  Thermal sensitivity across ages and during chronic fentanyl administration in rats.

Authors:  Jeremiah D Mitzelfelt; Christy S Carter; Drake Morgan
Journal:  Psychopharmacology (Berl)       Date:  2013-07-31       Impact factor: 4.530

7.  Astrocytic hypertrophy in the rat ventral tegmental area following chronic morphine differs with age.

Authors:  Emily C Goins; Dusica Bajic
Journal:  J Neurol Neurorehabilit Res       Date:  2018

8.  Pain And Opioid Systems, Implications In The Opioid Epidemic.

Authors:  Nicolas Massaly; Jose A Morón
Journal:  Curr Opin Behav Sci       Date:  2018-10-30

9.  Molecular mechanism for opioid dichotomy: bidirectional effect of μ-opioid receptors on P2X₃ receptor currents in rat sensory neurones.

Authors:  Igor Chizhmakov; Vyacheslav Kulyk; Iryna Khasabova; Sergey Khasabov; Donald Simone; Georgy Bakalkin; Dmitri Gordienko; Alexei Verkhratsky; Oleg Krishtal
Journal:  Purinergic Signal       Date:  2015-01-16       Impact factor: 3.765

10.  GpTx-1 and [Ala5 , Phe6 , Leu26 , Arg28 ]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level.

Authors:  Chao Chen; Biao Xu; Xuerui Shi; Mengna Zhang; Qinqin Zhang; Ting Zhang; Weidong Zhao; Run Zhang; Zilong Wang; Ning Li; Quan Fang
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.